Fig. 8
From: LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
Model of LRRK2 impact on pathology progression. a Graphical summary of major study findings. Near the pathology start site and highly connected regions, there was minimal effect of either LRRK2G2019S expression or LRRK2 kinase inhibition. However, in other regions, primarily cortical regions, there was an acceleration of tau pathology in LRRK2G2019S mice that was reversed with LRRK2 kinase inhibition. b Proposed use of regional measurements and progression modeling to assess the impact of therapies either preclinically or clinically. Tau pathology can be assessed in living patients by PET imaging. Further, tau PET signal progresses in a predictable fashion, with individual variability. We propose that rather than assessing single regions, it may be more valuable to sample broadly and model the impact of therapies on progression